The TROG 01.04 trial was designed to compare short-course (5 days of radiotherapy) and long- course (5.5 weeks of chemotherapy and radiotherapy) treatments delivered prior to cancer surgery in patients with localised rectal cancer. 326 patients were recruited into the trial. The results showed that at 5 years after treatment, the local recurrence rates were similar between both treatment groups.
The research also showed no differences in the risk of cancer spreading elsewhere in the body or in life expectancy between the two treatments. The trial confirmed that when delivered prior to cancer surgery, both short and long-course treatments are effective in the management of localised rectal cancer. Short-course radiotherapy may be an appropriate option for patients who cannot tolerate chemotherapy, and this treatment is easier to deliver. This allows cancer doctors to tailor personalised treatment decisions for individual patient needs.
The TROG 03.02 trial was launched to test the feasibility of a novel chemoradiation regimen for gastric cancer. The trial found that chemoradiation was feasible and could be safely delivered in a cooperative group setting. The three-year survival rate of 61.6 per cent was encouraging, especially given that many centres were implementing this treatment for the first time.
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292
